Meeting
2023 ASCO Annual Meeting
Effect of fecal transplantation on patients’ reported outcome after immune checkpoint inhibitor colitis.
Authors
Yinghong Wang
MD Anderson Cancer Center, Houston, TX
Yinghong Wang , Krishnavathana Varatharajalu , Malek Shatila , Shu-En Shen , Mary Herrera , Elizabeth Gonzalez , Xin Shelley Wang , Anusha Thomas , Zhi-Dong Jiang , Herbert L. DuPont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Clinical Trial Registration Number
NCT03819296
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2645)
DOI
10.1200/JCO.2023.41.16_suppl.2645
Abstract #
2645
Poster Bd #
487
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
First Author: Catriona Harvey
Poster
2022 ASCO Annual Meeting
Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma.
First Author: Liping Zhao
Poster
2021 ASCO Annual Meeting
Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
First Author: Hamzah Abu-Sbeih
Poster
2018 ASCO Annual Meeting
Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
First Author: Rosa Nadal